Sichuan University clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 107 studies whose lead sponsor is Sichuan University. 66 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 24, 2026.
Keep track of what changes. Save the Sichuan University studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 86
Focus areas
Conditions Sichuan University leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 107. Browse all 107 →
- Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory NeuroblastomaRecruitingNCT07767630Early Phase 1
- Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal MetastasesRecruitingNCT05477927Phase 1
- Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCRecruitingNCT07748325Phase 2
- Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLCRecruitingNCT06348797Phase 1
- A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07692048Phase 1
- Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical StudyNot yet recruitingNCT07665697
- Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical StudyNot yet recruitingNCT07665736
- Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingNCT07658872Phase 2
- Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic CancerNot yet recruitingNCT07637786Phase 1
- Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure:Phase I/IIRecruitingNCT06195189Phase 1/2
- Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerRecruitingNCT06431685Phase 1
- Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2
- Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver MetastasesNot yet recruitingNCT07258147Phase 2
- Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsRecruitingNCT06349837Phase 1
- Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCCRecruitingNCT07519486Phase 2
- Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruitingNCT07501169Phase 2
- Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)RecruitingNCT06610734Phase 2
- Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingNCT07374250Phase 2
- Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 InjectionNot yet recruitingNCT07362732Early Phase 1
- Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 InjectionNot yet recruitingNCT07332663Early Phase 1
- Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung CancerRecruitingNCT06877299Phase 2
- Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung CancerRecruitingNCT06121505Phase 2
- Oncolytic Virus in Esophageal Squamous Cell CarcinomaRecruitingNCT07061704Phase 1/2
- Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized TrialNot yet recruitingNCT07211009Phase 3
- Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal CancerNot yet recruitingNCT07154108Phase 1
- Lateral Positioning for Extubation After AdenotonsillectomyNot yet recruitingNCT07108218Not applicable
- Safety & Efficacy of IR-101 in Relapsed/Refractory NeuroblastomaRecruitingNCT07067346Early Phase 1
- A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingNCT06951464Phase 2
- The Intensive Nutritional Support in Esophageal Cancer Undergoing Neoadjuvant TherapyNot yet recruitingNCT07067359Not applicable
- Adjuvant Immunotherapy for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07067450Not applicable
- Application of KRAS Vaccine in the Treatment of KRAS-mutated MalignanciesRecruitingNCT07004244Phase 1
- High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System LymphomaRecruitingNCT07014943Phase 2
- Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
- Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in AdultsRecruitingNCT06347679Not applicable
- NAD+ Supplement(NMN)With Radioimmunotherapy in Advanced NSCLCNot yet recruitingNCT06966583Phase 1
- An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung CancerNot yet recruitingNCT06883552Phase 2
- Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale(PREDICT-PFO Trial)RecruitingNCT06863350Not applicable
- Personalized DC Vaccine for Postoperative CancerRecruitingNCT04147078Phase 1
- Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy As an Adjuvant Therapy for Pancreatic CancerRecruitingNCT06344156Phase 1
- A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLCRecruitingNCT06769295Phase 2
- Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLCRecruitingNCT06769971Phase 2
- Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCCRecruitingNCT06603402Phase 2
- Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid TumorsRecruitingNCT06084286Phase 1
- Neoantigen Vaccines in Esophageal Squamous Cell CarcinomaRecruitingNCT06675201Phase 2
- Dual-targeting HER2 and PD-L1 CAR-T for Solid TumorsRecruitingNCT04684459Early Phase 1
- The Effect of Aromatherapy for First Dental Visit PatientsNot yet recruitingNCT06598904Not applicable
- Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal CancerRecruitingNCT06403878Phase 2
- Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPCNot yet recruitingNCT06346808Phase 1
- Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT06229197Not applicable
- HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT06213519Phase 2